These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 11212131)

  • 1. Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients.
    Fisher E; Rudick RA; Cutter G; Baier M; Miller D; Weinstock-Guttman B; Mass MK; Dougherty DS; Simonian NA
    Mult Scler; 2000 Dec; 6(6):373-7. PubMed ID: 11212131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon beta-1a.
    Rudick RA; Fisher E; Lee JC; Duda JT; Simon J
    Mult Scler; 2000 Dec; 6(6):365-72. PubMed ID: 11212130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS.
    Rudick RA; Cutter G; Baier M; Fisher E; Dougherty D; Weinstock-Guttman B; Mass MK; Miller D; Simonian NA
    Neurology; 2001 May; 56(10):1324-30. PubMed ID: 11376182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients.
    Rudick RA; Cutter GR; Baier M; Weinstock-Guttman B; Mass MK; Fisher E; Miller DM; Sandrock AW
    Mult Scler; 2005 Dec; 11(6):626-34. PubMed ID: 16323317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eight-year follow-up study of brain atrophy in patients with MS.
    Fisher E; Rudick RA; Simon JH; Cutter G; Baier M; Lee JC; Miller D; Weinstock-Guttman B; Mass MK; Dougherty DS; Simonian NA
    Neurology; 2002 Nov; 59(9):1412-20. PubMed ID: 12427893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a.
    Gasperini C; Paolillo A; Giugni E; Galgani S; Bagnato F; Mainero C; Onesti E; Bastianello S; Pozzilli C
    Mult Scler; 2002 Apr; 8(2):119-23. PubMed ID: 11990868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebral atrophy and disability in relapsing-remitting and secondary progressive multiple sclerosis over four years.
    Turner B; Lin X; Calmon G; Roberts N; Blumhardt LD
    Mult Scler; 2003 Feb; 9(1):21-7. PubMed ID: 12617263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors that predict health-related quality of life in patients with relapsing-remitting multiple sclerosis.
    Miller DM; Rudick RA; Baier M; Cutter G; Doughtery DS; Weinstock-Guttman B; Mass MK; Fisher E; Simonian N
    Mult Scler; 2003 Feb; 9(1):1-5. PubMed ID: 12617260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing disability progression with the Multiple Sclerosis Functional Composite.
    Rudick RA; Polman CH; Cohen JA; Walton MK; Miller AE; Confavreux C; Lublin FD; Hutchinson M; O'Connor PW; Schwid SR; Balcer LJ; Lynn F; Panzara MA; Sandrock AW
    Mult Scler; 2009 Aug; 15(8):984-97. PubMed ID: 19667023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis.
    Baier ML; Cutter GR; Rudick RA; Miller D; Cohen JA; Weinstock-Guttman B; Mass M; Balcer LJ
    Neurology; 2005 Mar; 64(6):992-5. PubMed ID: 15781814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brain atrophy as a non-response predictor to interferon-beta in relapsing-remitting multiple sclerosis.
    Rojas JI; Patrucco L; Miguez J; Besada C; Cristiano E
    Neurol Res; 2014 Jul; 36(7):615-8. PubMed ID: 24620963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
    Kappos L; Traboulsee A; Constantinescu C; Erälinna JP; Forrestal F; Jongen P; Pollard J; Sandberg-Wollheim M; Sindic C; Stubinski B; Uitdehaag B; Li D
    Neurology; 2006 Sep; 67(6):944-53. PubMed ID: 17000959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
    Togha M; Karvigh SA; Nabavi M; Moghadam NB; Harirchian MH; Sahraian MA; Enzevaei A; Nourian A; Ghanaati H; Firouznia K; Jannati A; Shekiba M
    Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple sclerosis and depression: influence of interferon beta therapy.
    Zephir H; De Seze J; Stojkovic T; Delisse B; Ferriby D; Cabaret M; Vermersch P
    Mult Scler; 2003 Jun; 9(3):284-8. PubMed ID: 12814176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subcortical grey matter volumes predict subsequent walking function in early multiple sclerosis.
    Nourbakhsh B; Azevedo C; Maghzi AH; Spain R; Pelletier D; Waubant E
    J Neurol Sci; 2016 Jul; 366():229-233. PubMed ID: 27288812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined MRI lesions and relapses as a surrogate for disability in multiple sclerosis.
    Sormani MP; Li DK; Bruzzi P; Stubinski B; Cornelisse P; Rocak S; De Stefano N
    Neurology; 2011 Nov; 77(18):1684-90. PubMed ID: 21975200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients.
    Giovannoni G; Cohen JA; Coles AJ; Hartung HP; Havrdova E; Selmaj KW; Margolin DH; Lake SL; Kaup SM; Panzara MA; Compston DA;
    Neurology; 2016 Nov; 87(19):1985-1992. PubMed ID: 27733571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial.
    Ravnborg M; Sørensen PS; Andersson M; Celius EG; Jongen PJ; Elovaara I; Bartholomé E; Constantinescu CS; Beer K; Garde E; Sperling B
    Lancet Neurol; 2010 Jul; 9(7):672-80. PubMed ID: 20542736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing--remitting multiple sclerosis: results after 18 months of therapy.
    Khan OA; Tselis AC; Kamholz JA; Garbern JY; Lewis RA; Lisak RP
    Mult Scler; 2001 Dec; 7(6):349-53. PubMed ID: 11795454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy.
    Zivadinov R; Locatelli L; Cookfair D; Srinivasaraghavan B; Bertolotto A; Ukmar M; Bratina A; Maggiore C; Bosco A; Grop A; Catalan M; Zorzon M
    Mult Scler; 2007 May; 13(4):490-501. PubMed ID: 17463072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.